A two-day Centers for Disease Control and Prevention vaccine advisory committee meeting this week could dramatically shape the scope of Pfizer Inc./BioNTech SE’s US booter rollout for their mRNA COVID-19 vaccine Comirnaty.
CDC Vaccine Advisors Must Fill In Missing Holes On Pfizer’s COVID Booster Plan
ACIP will get a chance to further restrict and tailor the US booster plan for COVID vaccinations. Among other things, CDC's advisors may have to define what constitutes being at high risk of severe COVID-19 post-primary vaccination, occupations at high risk of COVID exposure, and whether people who didn’t receive Pfizer’s primary vaccine series could get the company’s mRNA booster shot.
